Contineum Therapeutics (CTNM) Non Operating Income (2023 - 2026)

Contineum Therapeutics' Non Operating Income history runs 4 years deep, the most recent figure standing at $2.3 million for Q2 2026.

• In Q2 2026, Non Operating Income rose 22.13% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $9.1 million (down 0.87% YoY), while the FY2025 annual figure was $8.1 million, down 6.43% from the prior year.
• Non Operating Income for Q2 2026 stood at $2.3 million, down from $2.4 million in the prior quarter.
• The five-year high for Non Operating Income was $3.4 million in Q2 2023, with the low at $291000.0 in Q1 2023.
• The 4-year median for Non Operating Income is $2.0 million (2025), against an average of $2.1 million.
• Peak annual rise in Non Operating Income reached 419.93% in 2024, while the deepest fall reached 42.34% in 2024.
• Contineum Therapeutics' Non Operating Income stood at $1.7 million in 2023, then surged by 42.15% to $2.5 million in 2024, then declined by 21.07% to $2.0 million in 2025, then increased by 16.08% to $2.3 million in 2026.
• Business Quant data shows CTNM's Non Operating Income at $2.3 million in Q2 2026, $2.4 million in Q1 2026, and $2.0 million in Q4 2025.